Chikungunya in the Americas: Recommendations and Conclusions

J Infect Dis. 2016 Dec 15;214(suppl 5):S510-S513. doi: 10.1093/infdis/jiw370.

Abstract

Discovered in 1953, chikungunya virus (CHIKV) circulated in Africa and Southeast Asia, with periodic outbreaks, for many years. Highly efficient transmission following a genetic mutation of the virus in 2005 caused its global spread. Associated with significant morbidity, CHIKV creates a large public health burden, and despite various efforts, there are currently no licensed vaccines nor specific treatments. To garner a better understanding of the virus, identify gaps in knowledge, and guide the development of more-effective interventions, the World Health Organization and National Institute of Allergy and Infectious Diseases assembled global experts for discussion and review. Herein described are the outcomes.

Keywords: Aedes aegypti; Aedes albopictus; CHIKV; alphavirus; chikungunya; chikungunya virus; virus-like particles.

MeSH terms

  • Aedes / virology
  • Americas
  • Animals
  • Chikungunya Fever / diagnosis
  • Chikungunya Fever / therapy*
  • Chikungunya Fever / transmission
  • Chikungunya Fever / virology
  • Chikungunya virus / genetics
  • Chikungunya virus / pathogenicity*
  • Disease Outbreaks
  • Humans
  • Mutation
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Practice Guidelines as Topic
  • United States
  • Viral Vaccines
  • World Health Organization

Substances

  • Viral Vaccines